Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NE-58095 DR vs IR in Involutional Osteoporosis
NCT02063854Phase 3Completed
- Sponsor
- Takeda
- Start
- Feb 2014
- Primary completion
- Nov 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of risedronate in involutional osteoporosis (7 arms), sponsored by Takeda. Primary endpoint: Percent Change From Baseline in Mean Lumbar Spine (L2-L4) Bone Mineral Density (BMD) at 12 months. Started Feb 2014; status: completed.
02
Drugs
risedronate
03
Conditions
involutional osteoporosis
Beyond the preview
Go deeper on NCT02063854.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02063854.